|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
Journal of Cell Science, Vol 109, Issue 9 2371-2381, Copyright © 1996 by Company of Biologists
JOURNAL ARTICLES |
CP Webb, K Lane, AP Dawson, GF Vande Woude and RM Warn
School of Biological Sciences, University of East Anglia, Norwich, Norfolk, UK.
The Met protein is a receptor tyrosine kinase for hepatocyte growth factor/scatter factor (HGF/SF), a multifunctional growth factor with mitogenic, motogenic and morphogenic properties. A morphologically altered variant of the MDCK cell line, MDCK-1, spontaneously exhibits a number of features associated with a partial HGF/SF-Met induced phenotype (less adhesive colonies in culture, enhanced invasion and motility, nascent tubule formation), but paradoxically does not respond to HGF/SF treatment. Although the overall cell surface expression and distribution of Met were found to be similar in parental MDCK cells and the MDCK-1 cell line, p145met autophosphorylation (+/ HGF/SF) was significantly reduced in MDCK-1 cells in vitro and in vivo when compared with parental MDCK cells. In contrast, EGF induced cell proliferation and EGF receptor autophosphorylation to similar levels in both cell lines. The basal levels of protein tyrosine phosphorylation were higher in MDCK-1 cells when compared with parental MDCK cells, including that of two prominent proteins with molecular masses of approximately 185 kDa and 220 kDa. Moreover, both p185 and p220 are present and tyrosine phosphorylated in Met immunoprecipitates from MDCK-1 cells (+/-HGF/SF), but not parental MDCK cells. In addition, Met immunocomplexes from MDCK-1 cells exhibited an approximately 3-fold increased tyrosine kinase activity in vitro when compared with MDCK cells, correlating with the higher basal levels of total phosphotyrosine. Treatment of MDCK-1 cells with the tyrosine kinase inhibitor herbimycin A reverted the cell phenotype to a more MDCK-like morphology in culture, with a concomitant reduction in the tyrosine phosphorylation predominantly of p220. Taken together these data suggest that aberrations in Met activity and associated signalling render MDCK-1 cells insensitive to HGF/SF, and may also mediate alterations in MDCK-1 cell behaviour.
This article has been cited by other articles:
|
|
 |
|
  B. Dekel, S. Biton, G. M. Yerushalmi, R. T. Altstock, L. Mittelman, D. Faletto, N. I. Smordinski, and I. Tsarfaty In situ activation pattern of Met docking site following renal injury and hypertrophy Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1493 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dekel, S. Biton, G. M. Yerushalmi, R. T. Altstock, L. Mittelman, D. Faletto, N. I. Smordinski, and I. Tsarfaty In situ activation pattern of Met docking site following renal injury and hypertrophy Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1493 - 1504. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Vadnais, G. Nault, Z. Daher, M. Amraei, Y. Dodier, I. R. Nabi, and J. Noel Autocrine Activation of the Hepatocyte Growth Factor Receptor/Met Tyrosine Kinase Induces Tumor Cell Motility by Regulating Pseudopodial Protrusion J. Biol. Chem., December 6, 2002; 277(50): 48342 - 48350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Webb, C. D. Hose, S. Koochekpour, M. Jeffers, M. Oskarsson, E. Sausville, A. Monks, and G. F. Vande Woude The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network Cancer Res., January 1, 2000; 60(2): 342 - 349. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Tulasne, R. Paumelle, K. M. Weidner, B. Vandenbunder, and V. Fafeur The Multisubstrate Docking Site of the MET Receptor Is Dispensable for MET-mediated RAS Signaling and Cell Scattering Mol. Biol. Cell, March 1, 1999; 10(3): 551 - 565. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. P. Webb, L. Van Aelst, M. H. Wigler, and G. F. Vande Woude Signaling pathways in Ras-mediated tumorigenicity and metastasis PNAS, July 21, 1998; 95(15): 8773 - 8778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Hordijk, J. P. ten Klooster, R. A. van der Kammen, F. Michiels, L. C. Oomen, and J. G. Collard Inhibition of Invasion of Epithelial Cells by Tiam1-Rac Signaling Science, November 21, 1997; 278(5342): 1464 - 1466. [Abstract] [Full Text]
|
|
|
|
|
|
M. Jeffers, L. Schmidt, N. Nakaigawa, C. P. Webb, G. Weirich, T. Kishida, B. Zbar, and G. F. Vande Woude Activating mutations for the Met tyrosine kinase receptor in human cancer PNAS, October 14, 1997; 94(21): 11445 - 11450. [Abstract] [Full Text] [PDF]
|
|
